Researchers at Helmholtz Munich have developed an experimental obesity treatment that combines two drug mechanisms into a single hybrid molecule, allowing a second therapeutic compound to enter cells by piggybacking on a well-established GLP-1/GIP receptor pathway. Early laboratory results show the approach dramatically outperforms current obesity medications in mice.
The strategy addresses a fundamental limitation of next-generation obesity drugs: adding extra metabolic benefits typically means exposing the entire body to additional chemicals, which often triggers unwanted side effects. The team's solution was to chemically fuse an incretin-based drug with a second compound called lanifibranor, creating what Prof Timo D. Müller describes as an "address label with cargo."
The incretin portion of the hybrid molecule acts as a delivery vehicle, binding to GLP-1 or GIP receptors on the cell surface. This opens the door for the molecule to enter. Once inside the cell, lanifibranor activates three separate PPAR "switches" in the cell nucleus, which control genes that regulate fat and sugar metabolism. The targeting is precise: the added metabolic effect concentrates in cells that express these specific receptors, rather than flooding the entire body with drug exposure.
Müller, director of the Institute for Diabetes and Obesity at Helmholtz Munich, compares the mechanism to a Trojan horse. "A major advantage is the amount," he explains. "Because the second component is not administered separately and systemically, but travels along with the incretin part, it can be used at a dose that is orders of magnitude lower." This targeted approach could translate to fewer side effects while maintaining or enhancing therapeutic benefit.
In mice bred to be obese, the hybrid drug produced striking results. Animals treated with the compound ate less and shed significantly more weight than mice given either a standard GLP-1/GIP combination drug or a GLP-1-only therapy. The treated mice also showed improved blood glucose control and signs of restored insulin sensitivity, meaning their bodies could move glucose from the bloodstream into tissues more efficiently. The liver also released less glucose into circulation.
The research team, led by Dr. Daniela Liskiewicz and Dr. Aaron Novikoff, observed that gastrointestinal side effects remained comparable to existing incretin drugs. Importantly, they detected no signs of fluid retention or anemia, concerns that can accompany the lanifibranor component when used separately as a systemic drug.
The findings, published in Nature, hint at additional benefits for heart and liver health, though Müller cautions that these observations are preliminary and limited to animal models. A critical unknown is whether the approach will work equally well in humans, particularly given that the GIP receptor differs between mice and people.
The research represents a preclinical proof of concept. Moving the therapy toward human trials will require optimization and partnerships with pharmaceutical companies. Müller acknowledges the gap between laboratory success and clinical application but frames the work as establishing a sound biological principle.
Author Jessica Williams: "This is clever engineering dressed as incretin therapy, but the mouse data is genuinely impressive, and the targeting strategy addresses a real problem that's plagued drug development in this space."
Comments